Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 1 · below the Ichimoku cloud · RSI 39 · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in ENDV in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ENDV trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ENDV.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -50.0 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.0 | −50.0% | ||
| 2025 | -25.0 | -33.3 | 0.0 | 0.0 | -50.0 | 60.0 | 25.0 | -50.0 | 0.0 | 100.0 | -30.0 | -28.6 | −75.0% |
| 2024 | -31.0 | -42.3 | -10.4 | -21.0 | -55.1 | -4.5 | -4.8 | 40.0 | -28.6 | 10.0 | -36.4 | -42.9 | −95.4% |
| 2023 | 4.4 | -26.1 | 19.0 | -39.5 | 48.0 | -2.0 | -24.1 | 15.5 | -0.8 | 10.3 | -17.3 | -24.3 | −51.7% |
| 2022 | 28.2 | -10.0 | -0.6 | -13.4 | -35.5 | -10.0 | -1.1 | -16.3 | -0.7 | 8.1 | -11.3 | 153.5 | +15.4% |
| 2021 | 139.0 | -26.7 | -2.6 | 22.4 | -20.6 | 13.9 | -33.9 | -12.4 | 25.9 | -20.4 | -12.5 | -19.2 | −22.4% |
| 2020 | 47.4 | -85.4 | -65.5 | 13.2 | -9.4 | -26.2 | -1.8 | -14.4 | 6.7 | -8.4 | -34.0 | -65.3 | −98.9% |
| 2019 | 50.5 | -24.5 | -20.3 | -29.7 | -7.6 | 51.1 | -30.2 | -8.0 | -7.7 | -37.6 | -49.9 | -36.7 | −89.6% |
| 2018 | -13.8 | -18.2 | -16.9 | -3.8 | 26.6 | -14.3 | -7.0 | 65.0 | -3.6 | -32.3 | -24.1 | -32.6 | −68.6% |
| 2017 | -32.3 | -55.6 | 253.3 | 62.1 | -32.5 | -51.7 | 25.0 | -24.3 | 117.7 | 12.0 | -13.2 | 3.4 | +16.2% |
| 2016 | 23.6 | -26.3 | 32.9 | 17.0 | -14.7 | -69.0 | 40.7 | -21.1 | -4.7 | -21.0 | -44.9 | -19.8 | −86.1% |
| 2015 | 0.0 | -16.0 | 4.8 | -9.1 | 0.0 | -31.1 | -15.9 | -86.2 | -12.5 | 42.9 | -20.0 | 350.1 | −71.2% |
| 2014 | 187.1 | 119.1 | -17.9 | -12.6 | -28.5 | -46.9 | 0.0 | -67.0 | 0.0 | -8.6 | -53.1 | 66.7 | −59.7% |
| 2013 | -26.7 | -54.5 | 0.0 | 4.4 | -4.0 | -24.2 | -34.2 | 0.0 | 0.0 | 24.0 | 0.0 | −79.3% |
No analyst coverage for this instrument.
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and peripheral artery disease (PAD) and ischemic stroke. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
No recent headlines.